Skip to main content

The independent medical news service

21-09-2020 | Breast cancer | Video

ESMO 2020 | Neoadjuvant atezolizumab plus chemotherapy supported for early TNBC

Nadia Harbeck presents the IMpassion031 study showing improved pathological complete responses with the addition of atezolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer.

20-09-2020 | Oncology | News | Article

IMpassion130: ‘Clinically meaningful’ OS boost with atezolizumab in PD-L1-positive advanced TNBC

The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.

18-09-2020 | Oncology | News | Article

FDA issues alert on atezolizumab–paclitaxel duo in breast cancer

Click through for the details of this announcement

16-09-2020 | Oncology | Highlight | Article

ctDNA accurately identifies breast cancer targeted therapy candidates

Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.

14-09-2020 | Oncology | News | Article

Long-term recurrence rates similar with partial vs whole breast irradiation

Long-term ipsilateral breast tumor recurrence rates are similar whether women are treated with accelerated partial-breast irradiation or whole-breast irradiation, results of the phase 3 APBI-IMRT-Florence trial show.

09-09-2020 | Oncology | News | Article

Meta-analysis indicates benefit of shorter trastuzumab duration in early breast cancer

In patients with early-stage breast cancer, shorter durations of adjuvant trastuzumab therapy are noninferior to the standard 1-year schedule with regard to disease-free survival, suggests an individual patient data meta-analysis.

Image Credits